

Finsbury Technology Trust PLC

Interim Report

for the six months to 31 May 2005



CLOSE FINSBURY
DIFFERENT BY DESIGN

CONTENTS

1	Company Summary	11	Balance Sheet
2	Chairman's Statement	12	Cash Flow Statement
3-5	Investment Adviser's Review	13-14	Notes to the Interim Financial Statements
6	Analysis of Portfolio and Performance Graph	15	Company Information
7-9	Investment Portfolio	16	Disability Act
10	Statement of Total Return		Investing with Finsbury Technology Trust PLC



A member of the Association of Investment Trust Companies

COMPANY SUMMARY

Performance Statistics

	31 May 2005	30 November 2004	% Change
Shareholders' Funds	£62.2m	£61.1m	+1.8
Net Asset Value per Ordinary share	225.1p	221.1p	+1.8
Share price	200.0p	200.5p	-0.2
Discount	11.2%	9.3%	-
MSCI World Index	1,502	1,415	+6.1

(sterling adjusted, without dividends reinvested)

Company Policy, Objective and Benchmark

Finsbury Technology Trust PLC invests principally in the equity securities of quoted technology companies on a worldwide basis with the aim of achieving long-term capital growth.

It is the Company's policy to invest no more than 15% of its gross assets in other listed investment companies (including listed investment trusts). The Company does not, at the time of this report, have any holdings in an investment company of any description.

Performance is measured against the Morgan Stanley Capital International ("MSCI") World Index (sterling adjusted, without dividends reinvested).

Interim Dividend

The Company has not declared an interim dividend (2004: nil).

Capital Structure

At 31 May 2005 the Company had 27,615,312 Ordinary shares of 25p each in issue.

Continuation Vote

Shareholders will have the opportunity to vote at the Annual General Meeting in 2006 whether to continue the Company and thereafter at five yearly intervals.

CHAIRMAN'S STATEMENT

Performance

During the six months ended 31 May 2005 the Company's net asset value ("NAV") per share rose from 221.1p to 225.1p, an increase of 1.8%. This compares with an increase of 3.4% in the NASDAQ Composite Index (sterling adjusted) and an increase of 6.1% in the MSCI World Index (sterling adjusted, without dividends reinvested), which is the Company's benchmark index. The Company's share price fell from 200.5p to 200.0p, a fall of 0.2%. The share price discount at the period end was 11.2% compared with 9.3% at 30 November 2004.

Results and Dividend

The result for the six months ended 31 May 2005 was a return of 4.0p per share (2004: loss of 16.3p per share). This was made up of a revenue loss of 1.7p per share (2004: loss of 2.0p per share) and a capital return of 5.7p per share (2004: loss of 14.3p per share).

The investments making up the Company's investment portfolio typically provide a very low yield and accordingly no dividend is recommended in respect of the six months ended 31 May 2005 (2004: Nil).

Board

I am delighted to welcome John Cornish to the Board. John was appointed as a director on 1 May 2005 and has a wealth of relevant experience. He retired from Deloitte & Touche as a senior partner on 31 May 2004. John will chair the Audit Committee with immediate effect.

Continuation vote

I referred to the forthcoming continuation vote in my statement covering the year ended 30 November 2004. In anticipation of the vote, your Board is in the process of concluding a thorough review of all aspects of the Company's affairs so as to be in a position to make an appropriate recommendation to shareholders.

Outlook

The past few years have been difficult for the technology sector, as expectations have been recalibrated following the extraordinary market of the dotcom boom. For those who invested at that time, recent results have been very disappointing. However, over a longer period, your Company has produced generally satisfactory returns.

Your Board continues to believe that there will be significant growth in the technology sector in the years ahead, with benefits likely for the long term investor.

David Quysner
Chairman
26 July 2005

INVESTMENT ADVISER'S REVIEW

During the six month period the Company's NAV per share rose by 1.8% compared with a rise of 6.1% for the benchmark, the MSCI World Index (sterling adjusted, without dividends reinvested) and a fall of 10.2% in the Russell 2000 Technology Index. The Company's technology portfolio rose by 4.2% whilst the biotechnology component, accounting for approximately 10% of the overall portfolio, fell by 17.4%.

After a strong December, technology shares fell steadily until May when there was a significant rally. Business conditions generally remained healthy although the biotechnology sector was weak following some well-publicised safety issues including the withdrawal of Tysabri after the deaths of some patients.

A number of technology areas outperformed, as successful consumer products including MP3 players and broadband grew strongly. Additionally, expectations for mobile phone sales were revised upwards. The growth of these sectors together with strong laptop sales resulted in a clearance of excess semiconductor inventories. This led to an improved performance in semiconductor stocks although volatility continued as the market remained concerned about the sustainability of the recovery.

Software and communication equipment stocks suffered from seasonality and a relatively saturated market. Encouragingly, the valuations of many software companies are now at such an attractive level that there are early signs of consolidation.

The USA

Increased regulatory pressures within the US market focused businesses on making sure that their IT systems functioned efficiently leading to a focus on working with existing suppliers, rather than buying products from new vendors. This, combined with normal seasonality, meant that some software companies had disappointing first quarter earnings, although results from the Company's software investments were generally good as our focus has been on companies offering solutions to "mission critical" problems.

The Company's holding in **Wind River Systems**, which focuses on device software optimisation performed strongly, after results that were considerably better than expectations. **Allscripts**, which is a recent purchase, was another good performer as its electronic medical record software performed well. The value inherent in many software companies attracted the attention of corporate buyers and there were a number of acquisitions, including **Niku**, **Ascential** and **Tecnomatix**, which were all stocks held in the investment portfolio.

The excess semiconductor inventories from last year were quickly cleared as the market for most electronic devices including MP3 players, laptop computers, and mobile phones grew faster than expectations, leading to better than expected earnings. Our top performing semiconductor stock was **Netlogic**, which sells communications processors.

INVESTMENT ADVISER'S REVIEW (Continued)

Communication stocks had a lacklustre period, falling slightly as business remained sluggish. **Foundry Networks** suffered disappointing earnings due to a delay in the signing of US government business. We continue to hold these shares, as we are confident as to the Company's future prospects.

Europe and Israel

The best performing stock in the whole portfolio was **DAT**, a new flotation stock providing device software management. We undertook extensive customer due diligence before making this investment and the stock rose significantly following the announcement that it was partnering with Dangaard to provide a Blackberry like service for delivering information wirelessly to handheld devices. **Soitec**, which is the world leader in insulator technology, performed strongly following outstanding results. In Scandinavia, **Framfab**, a European leader in internet consultancy services, performed well following good results indicating a successful turnaround.

Our worst performing stock was **Gresham Computing** which suffered from a slower than expected uptake of its main product which provides real time information on banks' currency positions. We remain confident that this company is in the process of building a major business and are intending to increase our position. **Superscape** also performed poorly, partly as a result of fund raising. While they still need to show that their games will sell they have positioned themselves for success.

Biotechnology

Our biotechnology shares had a disappointing period both in absolute and relative terms. Most individual stocks are extremely vulnerable to a set back in their leading product and **Neurochem** shares fell significantly as its leading product disappointed the market. **Dyax** shares also fell sharply when it had to reformulate its leading product with delays resulting in its development programme. Finally **Prometic** shares fell significantly following disappointing results and a problematic refinancing. Encouragingly **Ark Therapeutics** continued to meet the milestones that were promised when it went public and the shares recovered strongly. This company has a number of late stage products which if successful will enable it to emerge as a leading biotechnology company.

Outlook

We are becoming increasingly optimistic about the outlook for technology companies.

In the past decade, a huge technological infrastructure was put in place, based on computers, communication and network technologies, database software and the commercial implementation of the internet. Many companies in these and related sectors are due to benefit from an upgrade cycle as well as from the emergence of new products and markets that are developing around themes such as portable computing, VOIP, wireless LANs, WiMax, 3G and other technologies that give easy access to information and entertainment.

INVESTMENT ADVISER'S REVIEW (Continued)

The approaching upgrade cycle should ensure that short term growth rates for many companies in these sectors will exceed their long term trend and that of the overall market. Valuations are at attractive levels for these companies and this is leading to a consolidation in the industry. The losses suffered by technology investors over recent years should mean that capital is allocated cautiously and that capacity will remain tight, leading to a relatively benign pricing environment.

The emergence of a number of new markets which are often substantial but too small to be of interest to the major players in the sector is creating new opportunities which are the domain of smaller companies. Increased regulatory and cost pressures within the financial community mean that many such companies are not closely followed or researched, in our opinion leading to an inefficiently priced market for publicly traded smaller capitalisation technology stocks. This is the opportunity that your Company will endeavour to exploit. Our belief is that the technology sector is now out of favour at a time when the outlook is brightening and in our opinion investors who remain patient will be well rewarded.

Michael Bourne/Jeremy Gleeson

Rebourne Technology Investment Management Limited, *Investment Adviser*


Close Finsbury Asset Management Limited, *Investment Manager*

26 July 2005


ANALYSIS OF PORTFOLIO

as at 31 May 2005


Sector Analysis



Geographical Analysis



PERFORMANCE GRAPH



*Morgan Stanley Capital International World Index (sterling adjusted without dividends reinvested)

Figures have been rebased to 100 at launch (December 1995).

Source: Close Finsbury Asset Management Limited.

INVESTMENT PORTFOLIO

as at 31 May 2005

Investment	Sector	Country	Market Value £000	% of portfolio
Verisign	Internet	USA	2,142	3.4
Soitec	Semiconductors	France	1,907	3.1
Superscape	Software	UK	1,632	2.6
Mamut	Software	Norway	1,631	2.6
Retalix	Software	Israel	1,379	2.2
Check Point	Internet	Israel	1,373	2.2
Taiwan Semiconductor	Semiconductors	Taiwan	1,361	2.2
Juniper Networks	Communications	USA	1,344	2.2
Framtidsfabriken	Internet	Sweden	1,336	2.1
Wind River Systems	Design	USA	1,299	2.1
Top ten investments			15,404	24.7
Photo Me International	Hardware	UK	1,296	2.1
ASM International	Semiconductors	Netherlands	1,278	2.1
Bede	Semiconductors	UK	1,251	2.0
Citrix Systems	Software	USA	1,213	1.9
Infovista	Software	France	1,153	1.9
Akamai	Internet	USA	1,142	1.8
Altera	Semiconductors	USA	1,132	1.8
Ultratech	Semiconductors	USA	1,128	1.8
Parametric Technology	Design	USA	1,116	1.8
Applied Films	Hardware	USA	1,093	1.8
Top twenty investments			27,206	43.7
Imagination Technologies	Electronics (other)	UK	1,029	1.6
Broadcom	Communications	USA	994	1.6
Melexis	Components	Belgium	983	1.6
DSP Group	Communications	Israel	969	1.6
Allscripts Healthcare	Software	USA	960	1.5
Vanco	Communications	UK	949	1.5
Pharmaceutical Product Development	Biotechnology	USA	928	1.5
Ark Therapeutics	Biotechnology	UK	927	1.5
Powerdsine	Semiconductors	Israel	922	1.5
Vishay Intertechnology	Components	USA	910	1.5
Top thirty investments			36,777	59.1

INVESTMENT PORTFOLIO (Continued)

as at 31 May 2005

Investment	Sector	Country	Market Value £000	% of portfolio
DMX Technologies	Electronics (other)	Singapore	894	1.4
Entergisul	Electronics (other)	S Korea	887	1.4
Innovision Research and Technology	Semiconductors	UK	875	1.4
Netlogic Microsystems	Semiconductors	USA	858	1.4
Ceragon Networks	Communications	Israel	810	1.3
NXT Plc	Hardware	UK	808	1.3
Dicom	Software	UK	807	1.3
Digital River	Internet	USA	796	1.3
ECl Telecom	Communications	Israel	777	1.3
Manpower Software	Software	UK	771	1.2
Top forty investments			45,060	72.4
Gresham Computing	Software	UK	753	1.2
Orbotech	Hardware	Israel	717	1.1
Portrait Software	Software	UK	707	1.1
Foundry Networks	Communications	USA	674	1.1
Norman	Software	Norway	674	1.1
On Track Innovations	Hardware	Israel	654	1.1
Galapagos Genomics	Biotechnology	Belgium	649	1.0
Pharmacyclics	Biotechnology	USA	634	1.0
Palatin Technologies	Biotechnology	USA	622	1.0
Nepes	Components	S Korea	600	1.0
Top fifty investments			51,744	83.1
Niku	Software	USA	586	0.9
Pervasive Software	Software	USA	585	0.9
TTI Team Telecom	Communications	Israel	584	0.9
Cardiome Pharma	Biotechnology	Canada	548	0.9
24/7 Real Media	Internet	USA	546	0.9
Comino Group	Software	UK	533	0.9
Petards Group	Hardware	UK	488	0.8
DAT Group	Software	UK	477	0.8
Amino Technologies	Communications	UK	473	0.8
Prometic Life Sciences	Biotechnology	Canada	470	0.7
Top sixty investments			57,034	91.6

INVESTMENT PORTFOLIO (Continued)

as at 31 May 2005

Investment	Sector	Country	Market Value £000	% of portfolio
First Consulting	Software	USA	449	0.7
Redstone	Communications	UK	408	0.7
Zilog	Semiconductors	USA	403	0.7
Kornic Systems	Communications	S Korea	395	0.6
Microdose Technologies*	Biotechnology	USA	392	0.6
Cell Genesys	Biotechnology	USA	383	0.6
Cyprotex	Biotechnology	UK	341	0.6
Amcom Telecommunications	Communications	Australia	332	0.5
Parsytec Pattern	Software	Germany	319	0.5
Xantrex Technology	Biotechnology	Canada	314	0.5
Top seventy investments			60,770	97.6
Jenoptik	Semiconductor	Germany	311	0.5
Intelligent Environments Group	Software	UK	307	0.5
Psivida	Biotechnology	Australia	268	0.4
Stockeryale	Communications	USA	223	0.4
Carl Zeiss Medetic	Biotechnology	Germany	211	0.3
Insignia Solutions	Software	UK	67	0.1
Peregrine Systems	Software	USA	64	0.1
Auton Corporation	Hardware	Australia	25	0.1
Xenova Group	Biotechnology	UK	19	–
Authoriszor	Software	USA	1	–
Top eighty investments			62,266	100.0
Gentia Software*	Software	UK	–	–
Marchfirst Inc*	Internet	USA	–	–
Photoelectron*	Biotechnology	USA	–	–
Select Software	Software	USA	–	–
Total investments			62,266	100.0

* Unquoted Investments

STATEMENT OF TOTAL RETURN

Incorporating the revenue account for the six months ended 31 May 2005

	(Unaudited) Six months ended 31 May 2005			(Unaudited) Six months ended 31 May 2004			(Audited) Year ended 30 November 2004		
	Revenue £'000	Capital £'000	Total £'000	Revenue £'000	Capital £'000	Total £'000	Revenue £'000	Capital £'000	Total £'000
Gains/(losses) on investments	–	1,615	1,615	–	(3,869)	(3,869)	–	(6,099)	(6,099)
Exchange losses on currency balances	–	(22)	(22)	–	(81)	(81)	–	(104)	(104)
Income (note 2)	105	–	105	70	–	70	253	–	253
Investment management fees (note 3)	(327)	–	(327)	(370)	–	(370)	(677)	–	(677)
Other expenses	(221)	–	(221)	(226)	–	(226)	(417)	–	(417)
Net (loss)/return before finance costs and taxation	(443)	1,593	1,150	(526)	(3,950)	(4,476)	(841)	(6,203)	(7,044)
Interest payable and similar charges	(22)	–	(22)	(27)	–	(27)	(37)	–	(37)
(Loss)/return on ordinary activities before taxation	(465)	1,593	1,128	(553)	(3,950)	(4,503)	(878)	(6,203)	(7,081)
Taxation charge on ordinary activities	(8)	–	(8)	(5)	–	(5)	(23)	–	(23)
Transfer (from)/to reserves	(473)	1,593	1,120	(558)	(3,950)	(4,508)	(901)	(6,203)	(7,104)
(Loss)/return per Ordinary share – pence (note 4)	(1.7p)	5.7p	4.0p	(2.0p)	(14.3p)	(16.3p)	(3.2p)	(22.5p)	(25.7p)

BALANCE SHEET

as at 31 May 2005

	(Unaudited) 31 May 2005 £'000	(Unaudited) 31 May 2004 £'000	(Audited) 30 November 2004 £'000
Fixed asset investments	62,266	62,832	60,561
Current assets			
Debtors	2,398	69	1,687
Cash at bank	–	1,494	722
	2,398	1,563	2,409
Creditors			
Amounts falling due within one year	(2,491)	(746)	(1,917)
Net current (liabilities)/assets	(93)	817	492
Net assets	62,173	63,649	61,053
Capital and reserves			
Called up share capital	6,904	6,904	6,904
Share premium account	23,488	23,488	23,488
Capital reserve – realised	43,934	45,779	43,555
Capital reserve – unrealised	(4,127)	(5,312)	(5,341)
Revenue reserve	(8,026)	(7,210)	(7,553)
Total Shareholders' funds	62,173	63,649	61,053
Net asset value per Ordinary share (note 5)	225.1p	230.5p	221.1p

CASH FLOW STATEMENT

for the six months ended 31 May 2005

	(Unaudited) Six months ended 31 May 2005 £'000	(Unaudited) Six months ended 31 May 2004 £'000	(Audited) Year ended 30 November 2004 £'000
Net cash outflow from operating activities	(423)	(2,164)	(2,528)
Servicing of finance			
Bank overdraft and loan interest paid	(19)	(28)	(37)
Taxation			
Tax recovered	9	10	12
Financial investments			
Purchases of investments	(26,729)	(15,767)	(26,054)
Sales of investments	24,270	20,640	30,548
Net cash (outflow)/inflow from financial investment	(2,459)	4,873	4,494
Financing			
Drawdown/(repayment) of loans	2,000	(1,100)	(1,100)
Net cash inflow/(outflow) from financing	2,000	(1,100)	(1,100)
(Decrease)/increase in cash during the period	(892)	1,591	841
Reconciliation of net cash flow to movement in net (debt)/funds			
(Decrease)/increase in cash as above	(892)	1,591	841
Cash (inflow)/outflow from financing	(2,000)	1,100	1,100
Exchange movements	(22)	(82)	(104)
Movement in net (debt)/funds	(2,914)	2,609	1,837
Net funds/(debt) at start of period	722	(1,115)	(1,115)
Net (debt)/funds at end of period	(2,192)	1,494	722

NOTES TO THE INTERIM FINANCIAL STATEMENTS

1. Revenue Account

The revenue column of the Statement of Total Return represents the revenue account of the Company.

2. Income

	(Unaudited) Six months ended 31 May 2005 £'000	(Unaudited) Six months ended 31 May 2004 £'000	(Audited) Year ended 30 November 2004 £'000
Income from investments	94	65	221
Interest receivable and other income	11	5	32
	105	70	253

3. Investment management fees

	(Unaudited) Six months ended 31 May 2005 £'000	(Unaudited) Six months ended 31 May 2004 £'000	(Audited) Year ended 30 November 2004 £'000
Periodic fee	311	350	640
Performance fee	–	–	–
Irrecoverable VAT thereon	16	20	37
	327	370	677

4. (Loss)/return per Ordinary share

The revenue loss per Ordinary share is calculated by dividing the net revenue loss of £473,000 (six months ended 31 May 2004: £558,000; year ended 30 November 2004: £901,000) by 27,615,312 (six months ended 31 May 2004: 27,615,312; year ended 30 November 2004: 27,615,312) being the number of Ordinary shares in issue during the period. The capital return per Ordinary share is calculated by dividing the net capital return of £1,593,000 (six months ended 31 May 2004: loss of £3,950,000; year ended 30 November 2004: loss of £6,203,000) by the number of Ordinary shares, as above.

NOTES TO THE INTERIM FINANCIAL STATEMENTS (Continued)

5. Net Asset Value per Ordinary share

	(Unaudited) Six months ended 31 May 2005 £'000	(Unaudited) Six months ended 31 May 2004 £'000	(Audited) Year ended 30 November 2004 £'000
Net asset value per Ordinary share	225.1p	230.5p	221.1p

The net asset value per Ordinary share is based on the assets attributable to ordinary shareholders of £62,173,000 (six months ended 31 May 2004: £63,649,000; year ended 30 November 2004: £61,053,000) and on 27,615,312 Ordinary shares (31 May 2004: 27,615,312; 30 November 2004: 27,615,312) being the number of Ordinary shares in issue at the end of the period.

6. Comparative information

The figures and financial information for the year ended 30 November 2004 are an extract from the latest published financial statements and do not constitute statutory financial statements for that year. Those financial statements have been delivered to the Registrar of Companies and included the report of the auditors which was unqualified and did not contain a statement under either section 237(2) and 237(3) of the Companies Act 1985.

The interim financial statements have been neither audited nor reviewed by the Company's auditors. They have been prepared using the same accounting policies as those adopted in the financial statements for the year ended 30 November 2004.

COMPANY INFORMATION

Directors

David Quysner (Chairman)
John Cornish
Paul Gaunt
Dr Chris Martin
Dr David Potter
Anthony Townsend

Company Secretary

Close Finsbury Asset Management Limited
10 Crown Place, London EC2A 4FT
Authorised and Regulated by the Financial Services Authority

Registered Office

10 Crown Place, London EC2A 4FT
Telephone: 020 7426 4000

Company Registration Number

3117355 (Registered in England)

Investment Manager

Close Finsbury Asset Management Limited
10 Crown Place, London EC2A 4FT
Authorised and Regulated by the Financial Services Authority

Investment Adviser

Rebourne Technology Investment
Management Limited
4 Crown Place, London EC2A 4BT

Registrars

Capita IRG plc
The Registry, 34 Beckenham Road,
Beckenham, Kent BR3 4TU
Telephone: 0870 162 3100
Facsimilie: 020 8639 2342
E-mail: ssd@capitaregistrars.com

Please contact the Registrars if you have a query about a certificated holding in the Company's shares.

Auditors

RSM Robson Rhodes LLP
186 City Road, London EC1V 2NU

Stockbrokers

JPMorgan Cazenove Limited
20 Moorgate, London EC2R 6DA

Close Finsbury ISA, Savings Scheme and PEP

Block C, Western House, Lynchwood
Business Park, Peterborough, PE2 6BP
Investor Helpline: 0800 169 6968*
Professional Advisers Helpline:
020 7426 4372
E-Mail: info@closefinsbury.com

*Calls to this number are recorded for monitoring purposes.

Please contact the Investor Helpline to obtain information and literature concerning the Company or other Close Finsbury investment trusts, or if you have a query concerning a Close Finsbury ISA, Savings Scheme or PEP account.

Online investment and account management is available for the Close Finsbury ISA, Savings Scheme and PEP at www.closefinsbury.com

Share Price Listings

The price of your shares can be found in various publications including the Financial Times under the heading Investment Companies and in the Daily Telegraph under the heading Investment Trusts.

The Company's net asset value per share is announced daily and is available on the Close Finsbury website at www.closefinsbury.com and on the TrustNet website at www.trustnet.com

Identification Codes

Ordinary shares: SEDOL	: 0339072
ISIN	: GB000339072
BLOOMBERG:	FTT LN
EPIC	: FTT

Disability Act

Copies of this interim report and other documents issued by the Company are available from the Company Secretary. If needed, copies can be made available in a variety of formats, including braille, audio tape or larger type as appropriate. You can contact the Registrar to the Company, Capita IRG plc, which has installed telephones to allow speech and hearing impaired people who have their own telephone to contact them directly, without the need for an intermediate operator, for this service please call 020 8639 2062. Specially trained operators are available during normal business hours to answer queries via this service. Alternatively, if you prefer to go through a 'typetalk' operator (provided by The Royal National Institute for Deaf People) you should dial 18001 from your textphone followed by the number you wish to dial.

INVESTING WITH FINSBURY TECHNOLOGY TRUST PLC

There are a variety of ways you can buy shares in the Company. You have the choice of lump sum or regular savings within a Close Finsbury ISA or Savings Scheme. There is also a PEP transfer facility if you already hold a PEP. Alternatively you can buy shares direct through your stockbroker or bank.

Although the Company does not anticipate paying dividends, if you hold other shares within the Close Finsbury Schemes, you have the benefit of automatic income reinvestment, therefore compounding your returns.

The **CLOSE FINSBURY ISA**

– enables investors to invest tax free up to £7,000 each year

The **CLOSE FINSBURY SAVINGS SCHEME**

– is open to lump sum investment or regular savings

A **SAVING FOR CHILDREN** facility

– is available within the Savings Scheme

Investment in the ISA and Savings Scheme can be made by lump sum from £1,000 or regular monthly savings from as little as £100 per month. Once invested, you can top up your Schemes at any time subject to a minimum of £100.

The **CLOSE FINSBURY PEP TRANSFER**

– can be used to transfer the value of your existing PEP. A minimum of £1,000 can be invested in shares of the Company.

You can open an account and deal **ONLINE** for the ISA and Savings Scheme on the Close Finsbury website www.closefinsbury.com. Account management for all the Investment Schemes is also available on the website. This enables you to:

Access your account 24 hours a day	Amend your personal details
Obtain up-to-date valuations	Change Direct Debit details
View current and historic statements	Set up income payments
Purchase online by debit card	Sell online

To find out more either:

Phone: 0800 169 6968*
Click: www.closefinsbury.com
Email: info@closefinsbury.com

All of the Close Finsbury managed investment trusts are available within the Close Finsbury ISA, Savings Scheme or PEP. The range includes:

Close Finsbury EuroTech Trust PLC
Finsbury Growth & Income Trust PLC
Finsbury Emerging Biotechnology Trust PLC
Finsbury Technology Trust PLC
Finsbury Worldwide Pharmaceutical Trust PLC

*calls to this number are recorded for monitoring purposes
Close Finsbury Asset Management Limited is authorised and regulated by the Financial Services Authority

